nanoDERM Sciences
Early-stage developer of diagnostic and therapeutic products focused on hydrogel-based nanoparticle drug delivery and targeted nanomedicine for wound healing and infectious disease. The company develops a patented biodegradable, thermal-responsive copolymer hydrogel platform for controlled-release formulations and antibacterial therapies targeting drug-resistant bacteria, with proof-of-concept work supported by government R&D contracts.
Industries
Nr. of Employees
small (1-50)
nanoDERM Sciences
Arlington, Virginia, United States, North America
Patents
Products
Patented hydrogel copolymer drug delivery platform
A biodegradable, thermal-responsive copolymer hydrogel platform developed for nanoparticle drug delivery and controlled-release applications (patented by the company).
Wound healing dressing with integrated drug delivery
A wound dressing concept that integrates the hydrogel platform to provide localized, controlled-release delivery of therapeutic agents for advanced wound healing.
Antibacterial nanomedicine prototypes for burn wound infections
Preclinical antibacterial nanoparticle formulations developed and tested in vitro to target multidrug-resistant bacteria implicated in burn wound sepsis and bacteremia.
HydroDEX
A patented copolymer molecule synthesized from FDA-approved Dextran and another FDA-approved polymer, functioning as a high capacity, non-toxic, biocompatible, thermal-responsive, and biodegradable hydrogel for controlled nanoparticle drug delivery and advanced wound healing dressings.
Patented hydrogel copolymer drug delivery platform
A biodegradable, thermal-responsive copolymer hydrogel platform developed for nanoparticle drug delivery and controlled-release applications (patented by the company).
Wound healing dressing with integrated drug delivery
A wound dressing concept that integrates the hydrogel platform to provide localized, controlled-release delivery of therapeutic agents for advanced wound healing.
Antibacterial nanomedicine prototypes for burn wound infections
Preclinical antibacterial nanoparticle formulations developed and tested in vitro to target multidrug-resistant bacteria implicated in burn wound sepsis and bacteremia.
HydroDEX
A patented copolymer molecule synthesized from FDA-approved Dextran and another FDA-approved polymer, functioning as a high capacity, non-toxic, biocompatible, thermal-responsive, and biodegradable hydrogel for controlled nanoparticle drug delivery and advanced wound healing dressings.
Expertise Areas
- Nanoparticle drug delivery
- Hydrogel biomaterials
- Antibacterial therapeutic development
- Wound healing therapy development
Key Technologies
- Hydrogel-based drug delivery
- Biodegradable copolymer synthesis
- Thermal-responsive polymers
- Controlled-release formulation
News & Updates
Invited presentation and abstract award at the 2012 Drug Delivery Partnerships Meeting (Las Vegas) describing the novel hydrogel platform.
Recipient of the 10th Award of the Joint Technology Transfer Initiative for novel antibacterial nanomedicine targeting burn wound infections (one-year Proof-of-Concept R&D grant funded by the Department of Homeland Security).
Awarded a 2015 DHP SBIR Phase I feasibility contract that delivered a working antibacterial prototype targeting drug-resistant bacteria.
A five-year Defense Health Program contract delivered proof-of-concept in vitro data demonstrating antibacterial activity of the hydrogel platform against multidrug-resistant bacteria.
The core copolymer hydrogel platform is described as patented by the company.
Invited presentation and abstract award at the 2012 Drug Delivery Partnerships Meeting (Las Vegas) describing the novel hydrogel platform.
Recipient of the 10th Award of the Joint Technology Transfer Initiative for novel antibacterial nanomedicine targeting burn wound infections (one-year Proof-of-Concept R&D grant funded by the Department of Homeland Security).
Awarded a 2015 DHP SBIR Phase I feasibility contract that delivered a working antibacterial prototype targeting drug-resistant bacteria.
A five-year Defense Health Program contract delivered proof-of-concept in vitro data demonstrating antibacterial activity of the hydrogel platform against multidrug-resistant bacteria.
The core copolymer hydrogel platform is described as patented by the company.